A real-world cohort study finds that denosumab use is linked to a lower risk for incident knee osteoarthritis in adults with osteoporosis than the use of bisphosphonates.

Longer durations of denosumab treatment improved the probability of achieving target T-scores at the total hip and lumbar spine in postmenopausal women with osteoporosis. Denosumab treatment ...

Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis who received more than one dose of denosumab had a reduced risk for developing diabetes ...

Biosimilar CT-P41 showed comparable efficacy and safety to reference denosumab for treating osteoporosis among postmenopausal women. CT-P41, a biosimilar candidate for denosumab, demonstrates efficacy ...

During the first 12 weeks of treatment, 41.1% of women on denosumab developed severe hypocalcemia compared with 2.0% of those taking oral bisphosphonates, reported a group of largely FDA researchers ...

Please provide your email address to receive an email when new articles are posted on . A denosumab biosimilar candidate demonstrated noninferior efficacy to its reference product, with similar safety ...

Prolia® is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily ...

Continued denosumab treatment is associated with a lower risk for diabetes in adults with osteoporosis older than 65 years, found a large-scale cohort study in Taiwan. Denosumab, used in osteoporosis ...

The BLA is supported by a comprehensive data package that includes data from the phase 1/3 ROSALIA study. The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) ...

Denosumab is indicated for treating osteoporosis in postmenopausal women, preventing skeletal-related complications in cancer that has spread to the bone and treating unresectable giant cell tumor of ...